Document is current
Any future updates will be listed below
-
Authors
Tantawy, Shady I.
Aslan, Burcu
Manyam, Ganiraju https://orcid.org/0000-0001-6006-8961
Iles, LaKesla R.
Timofeeva, Natalia https://orcid.org/0000-0002-6985-3509
Singh, Neetu
Jain, Nitin
Ferrajoli, Alessandra https://orcid.org/0000-0001-9547-4193
Thompson, Philip A.
Patel, Keyur P. https://orcid.org/0000-0001-5081-2427
Desikan, Sai Prasad https://orcid.org/0000-0003-1157-6489
Wierda, William G. https://orcid.org/0000-0002-7357-270X
Gandhi, Varsha https://orcid.org/0000-0002-3172-9166
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Center for Scientific Review (P30 CA016672)
Eli Lilly and Company (Loxo/Lilly SRA)
- License Information
-
More Information
Article History
Received: 18 March 2025
Revised: 31 August 2025
Accepted: 18 September 2025
First Online: 27 October 2025
Competing interests
: Specifically, for the current investigations, VG received a sponsored research agreement from Loxo Oncology (now a subsidiary of Lilly Oncology). Previously, for other investigations, VG received research funding from Pharmacyclics, Acerta, Gilead, Sunesis, Infinity, AbbVie, and Clear Creek Bio. WGW received research funding from GSK/Novartis, AbbVie, Genentech, Pharmacyclics LLC, AstraZeneca/Acerta Pharma, Gilead Sciences, Juno Therapeutics, KITE Pharma, Sunesis, Miragen, Oncternal Therapeutics, Inc., Cyclacel, Loxo Oncology, Inc., Janssen, Xencor. The remaining authors declare no competing financial interests. Consultancy/honoraria: AbbVie, Ascentage, AstraZeneca, Beigene, Genmab, Janssen, Lilly, Merck. Speaker fees: AbbVie, AstraZeneca, Beigene, Janssen, Roche.
